In vitro aerosol delivery and regional airway surface liquid concentration of a liposomal cationic peptide

Carlos F. Lange, Robert Hancock, John Samuel, Warren H. Finlay

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

A liposome encapsulation was optimized for the entrapment and aerosol delivery of an α-helical cationic peptide, CM3, which had shown good antimicrobial and antiendotoxin activity in vitro. The encapsulation procedure and the phospholipids used were selected to maximize both the encapsulation and nebulization efficiencies, without compromising liposomal integrity during nebulization. The best compromise was found with dimyristoyl phosphatidylcholine and dimyristoyl phosphatidylglycerol (3:1 molar ratio), which allowed for peptide encapsulation levels of 730 μg/mL using 30 mM lipid concentration. The aerosol produced with the selected liposomal formulation was subsequently analyzed for determination of size distribution and nebulizer efficiencies. These quantities were used as input for a mathematical lung deposition model, which predicted local lung depositions of the liposomal peptides for three models of lung geometry and breathing patterns: an adult, an 8-year-old child, and a 4-year-old child. The deposition results were then applied to a novel model of airway surface liquid in the lung to assess the concentration of the deposited peptide. The resulting concentration estimates indicate that the minimum inhibitory levels of CM3 can be reached over most part of the tracheobronchial region in the adult model, and can be exceeded throughout the same region in both pediatric model subjects, using a valved jet nebulizer with a 2.5mL volume fill.

LanguageEnglish
Pages1647-1657
Number of pages11
JournalJournal of Pharmaceutical Sciences
Volume90
Issue number10
DOIs
Publication statusPublished - 1 Jan 2001
Externally publishedYes

Keywords

  • Cationic peptide
  • Liposome encapsulation
  • Lung deposition simulation
  • Nebulization efficiency

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

@article{54e6d901caf949849db1c7f5f0b72727,
title = "In vitro aerosol delivery and regional airway surface liquid concentration of a liposomal cationic peptide",
abstract = "A liposome encapsulation was optimized for the entrapment and aerosol delivery of an α-helical cationic peptide, CM3, which had shown good antimicrobial and antiendotoxin activity in vitro. The encapsulation procedure and the phospholipids used were selected to maximize both the encapsulation and nebulization efficiencies, without compromising liposomal integrity during nebulization. The best compromise was found with dimyristoyl phosphatidylcholine and dimyristoyl phosphatidylglycerol (3:1 molar ratio), which allowed for peptide encapsulation levels of 730 μg/mL using 30 mM lipid concentration. The aerosol produced with the selected liposomal formulation was subsequently analyzed for determination of size distribution and nebulizer efficiencies. These quantities were used as input for a mathematical lung deposition model, which predicted local lung depositions of the liposomal peptides for three models of lung geometry and breathing patterns: an adult, an 8-year-old child, and a 4-year-old child. The deposition results were then applied to a novel model of airway surface liquid in the lung to assess the concentration of the deposited peptide. The resulting concentration estimates indicate that the minimum inhibitory levels of CM3 can be reached over most part of the tracheobronchial region in the adult model, and can be exceeded throughout the same region in both pediatric model subjects, using a valved jet nebulizer with a 2.5mL volume fill.",
keywords = "Cationic peptide, Liposome encapsulation, Lung deposition simulation, Nebulization efficiency",
author = "Lange, {Carlos F.} and Robert Hancock and John Samuel and Finlay, {Warren H.}",
year = "2001",
month = "1",
day = "1",
doi = "10.1002/jps.1115",
language = "English",
volume = "90",
pages = "1647--1657",
journal = "Journal of Pharmaceutical Sciences",
issn = "0022-3549",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

In vitro aerosol delivery and regional airway surface liquid concentration of a liposomal cationic peptide. / Lange, Carlos F.; Hancock, Robert; Samuel, John; Finlay, Warren H.

In: Journal of Pharmaceutical Sciences, Vol. 90, No. 10, 01.01.2001, p. 1647-1657.

Research output: Contribution to journalArticle

TY - JOUR

T1 - In vitro aerosol delivery and regional airway surface liquid concentration of a liposomal cationic peptide

AU - Lange, Carlos F.

AU - Hancock, Robert

AU - Samuel, John

AU - Finlay, Warren H.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - A liposome encapsulation was optimized for the entrapment and aerosol delivery of an α-helical cationic peptide, CM3, which had shown good antimicrobial and antiendotoxin activity in vitro. The encapsulation procedure and the phospholipids used were selected to maximize both the encapsulation and nebulization efficiencies, without compromising liposomal integrity during nebulization. The best compromise was found with dimyristoyl phosphatidylcholine and dimyristoyl phosphatidylglycerol (3:1 molar ratio), which allowed for peptide encapsulation levels of 730 μg/mL using 30 mM lipid concentration. The aerosol produced with the selected liposomal formulation was subsequently analyzed for determination of size distribution and nebulizer efficiencies. These quantities were used as input for a mathematical lung deposition model, which predicted local lung depositions of the liposomal peptides for three models of lung geometry and breathing patterns: an adult, an 8-year-old child, and a 4-year-old child. The deposition results were then applied to a novel model of airway surface liquid in the lung to assess the concentration of the deposited peptide. The resulting concentration estimates indicate that the minimum inhibitory levels of CM3 can be reached over most part of the tracheobronchial region in the adult model, and can be exceeded throughout the same region in both pediatric model subjects, using a valved jet nebulizer with a 2.5mL volume fill.

AB - A liposome encapsulation was optimized for the entrapment and aerosol delivery of an α-helical cationic peptide, CM3, which had shown good antimicrobial and antiendotoxin activity in vitro. The encapsulation procedure and the phospholipids used were selected to maximize both the encapsulation and nebulization efficiencies, without compromising liposomal integrity during nebulization. The best compromise was found with dimyristoyl phosphatidylcholine and dimyristoyl phosphatidylglycerol (3:1 molar ratio), which allowed for peptide encapsulation levels of 730 μg/mL using 30 mM lipid concentration. The aerosol produced with the selected liposomal formulation was subsequently analyzed for determination of size distribution and nebulizer efficiencies. These quantities were used as input for a mathematical lung deposition model, which predicted local lung depositions of the liposomal peptides for three models of lung geometry and breathing patterns: an adult, an 8-year-old child, and a 4-year-old child. The deposition results were then applied to a novel model of airway surface liquid in the lung to assess the concentration of the deposited peptide. The resulting concentration estimates indicate that the minimum inhibitory levels of CM3 can be reached over most part of the tracheobronchial region in the adult model, and can be exceeded throughout the same region in both pediatric model subjects, using a valved jet nebulizer with a 2.5mL volume fill.

KW - Cationic peptide

KW - Liposome encapsulation

KW - Lung deposition simulation

KW - Nebulization efficiency

UR - http://www.scopus.com/inward/record.url?scp=0034758170&partnerID=8YFLogxK

U2 - 10.1002/jps.1115

DO - 10.1002/jps.1115

M3 - Article

VL - 90

SP - 1647

EP - 1657

JO - Journal of Pharmaceutical Sciences

T2 - Journal of Pharmaceutical Sciences

JF - Journal of Pharmaceutical Sciences

SN - 0022-3549

IS - 10

ER -